NZ594010A - Novel forms of bendamustine free base - Google Patents

Novel forms of bendamustine free base

Info

Publication number
NZ594010A
NZ594010A NZ594010A NZ59401010A NZ594010A NZ 594010 A NZ594010 A NZ 594010A NZ 594010 A NZ594010 A NZ 594010A NZ 59401010 A NZ59401010 A NZ 59401010A NZ 594010 A NZ594010 A NZ 594010A
Authority
NZ
New Zealand
Prior art keywords
free base
bendamustine free
forms
novel forms
bendamustine
Prior art date
Application number
NZ594010A
Other languages
English (en)
Inventor
Mark Eddleston
Curtis R Haltiwanger
Laurent D Courvoisier
Robert E Mckean
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ594010(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NZ594010A publication Critical patent/NZ594010A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
NZ594010A 2009-01-15 2010-01-14 Novel forms of bendamustine free base NZ594010A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14484309P 2009-01-15 2009-01-15
PCT/US2010/020992 WO2010083276A1 (en) 2009-01-15 2010-01-14 Novel forms of bendamustine free base

Publications (1)

Publication Number Publication Date
NZ594010A true NZ594010A (en) 2013-08-30

Family

ID=42008533

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ594010A NZ594010A (en) 2009-01-15 2010-01-14 Novel forms of bendamustine free base

Country Status (16)

Country Link
US (1) US8076366B2 (enExample)
EP (1) EP2387400A1 (enExample)
JP (1) JP2012515210A (enExample)
KR (1) KR20110110293A (enExample)
CN (2) CN103554030A (enExample)
AU (2) AU2010204765A1 (enExample)
BR (1) BRPI1004922A2 (enExample)
CA (1) CA2749101A1 (enExample)
EA (1) EA020767B1 (enExample)
IL (1) IL213725A0 (enExample)
MX (1) MX2011007557A (enExample)
NZ (1) NZ594010A (enExample)
SG (1) SG172810A1 (enExample)
UA (1) UA109109C2 (enExample)
WO (1) WO2010083276A1 (enExample)
ZA (1) ZA201105099B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2516404A4 (en) * 2009-12-23 2013-04-17 Reddys Lab Ltd Dr PREPARATION OF BENDAMUSTINE AND ITS SALTS
PL3158991T3 (pl) 2010-01-28 2021-09-27 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
EP2720547A4 (en) * 2011-06-20 2014-11-05 Hetero Research Foundation PROCESS FOR BENDAMUSTINE HYDROCHLORIDE
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP2827863B1 (en) 2012-03-20 2019-01-16 Eagle Pharmaceuticals, Inc. Liquid composition for use in a method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
JP6250628B2 (ja) 2012-03-20 2017-12-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
CA2904143A1 (en) 2013-03-12 2014-10-09 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
EP4218543A1 (en) 2013-04-26 2023-08-02 Genentech, Inc. Contour integration perimetry vision test
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80967C (enExample)
DE293808C (enExample)
DE159877C (enExample)
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
DE122004000036I1 (de) 1992-11-13 2005-07-07 Biogen Idec Inc Therapeutische Verwendung von chimerischen und markierten Antik¦rper gegen menschlichen B Lymphozyt beschr{nkter Differenzierung antigen f}r die Behandlung von B-Zell-Lymphoma.
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1995011683A1 (en) 1993-10-27 1995-05-04 The Upjohn Company Stabilized prostaglandin e¿1?
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
US20040072889A1 (en) 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
AU767586B2 (en) 1998-07-09 2003-11-20 Cephalon, Inc. Methods and compositions for the treatment of chronic lymphocytic leukemia
US5972912A (en) 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
HUP0400683A2 (hu) 2000-12-11 2004-06-28 Takeda Chemical Industries, Ltd. HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény
CA2431319A1 (en) 2000-12-11 2002-06-20 Hiroto Bando Pharmaceutical composition having an improved water solubility
BR0213279A (pt) 2001-10-15 2004-10-26 Hemoteq Gmbh Revestimento de stents para impedir a restenose
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
AU2003221517B2 (en) 2002-03-22 2010-02-18 Christian Straka Cytocapacity test
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
DE10393060D2 (de) 2002-05-09 2005-05-04 Hemoteq Gmbh Reduktion der Schallemission von dünnwadigen Bauteilen in Magnetresonazgeräten
US20040096436A1 (en) 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
US7157551B2 (en) 2003-02-14 2007-01-02 Cephalon, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
WO2005011688A1 (en) 2003-07-25 2005-02-10 Wyeth Cci-779 lyophilized formulations
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AU2009302493B2 (en) * 2008-10-08 2015-04-09 Cephalon Llc Processes for the preparation of bendamustine

Also Published As

Publication number Publication date
KR20110110293A (ko) 2011-10-06
WO2010083276A1 (en) 2010-07-22
CA2749101A1 (en) 2010-07-22
ZA201105099B (en) 2012-03-28
IL213725A0 (en) 2011-07-31
AU2016204902A1 (en) 2016-08-04
EA020767B1 (ru) 2015-01-30
EA201170934A1 (ru) 2011-12-30
SG172810A1 (en) 2011-08-29
JP2012515210A (ja) 2012-07-05
BRPI1004922A2 (pt) 2019-09-24
US20100210701A1 (en) 2010-08-19
EP2387400A1 (en) 2011-11-23
CN102281877B (zh) 2014-07-23
US8076366B2 (en) 2011-12-13
CN102281877A (zh) 2011-12-14
AU2010204765A1 (en) 2011-07-28
MX2011007557A (es) 2011-08-12
CN103554030A (zh) 2014-02-05
UA109109C2 (uk) 2015-07-27

Similar Documents

Publication Publication Date Title
NZ594010A (en) Novel forms of bendamustine free base
MX342913B (es) Formas solidas de romidepsina y sus usos.
HUE036085T2 (hu) Nagy tisztaságú és kristályos dimetil-fumarát elõállítására szolgáló eljárás
ZA200908231B (en) Stevioside polymorphic and amorphous forms,methods for their formulation,and uses
PT2247582T (pt) Forma cristalina anidra do dimetoxidocetaxel e métodos para a preparação do mesmo
EP2480079A4 (en) PYRIDO- (3,4-B-) INDOLE AND USE METHOD THEREFOR
WO2009120386A3 (en) Novel solid forms of bendamustine hydrochloride
WO2007136510A3 (en) Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
MX2015003124A (es) Formas polimorficas de enzalutamida y su preparacion.
JO2887B1 (en) Spiro-pyridine compounds as ORL-1 receptor antagonists
SI2963024T1 (sl) Kristalinični hidrati metiltioninijevega klorida-del 2
IL225647A0 (en) Crystalline forms of the dihydrochloride salt of (4a – r, 9a – s) – 1 – (1h – benzoimidazole – 5 carbonyl) – 2, 3, 4, 4a, 9, 9a – hexahydro – 1h – indo [1,2 –b ] pyridine - 6 carbonitrile and their use as 1 hsd inhibitors
UA99787C2 (en) Lactams as beta secretase inhibitors
PH12012502252A1 (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
PH12015500733A1 (en) Method of weight management
IL214421A0 (en) Methods for producing human amniotic cell lines
IL221461A0 (en) Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
UA105767C2 (uk) Аморфна форма протіоконазолу, бактерицидна композиція на її основі, способи їх одержання
MX343234B (es) Formas cristalinas de 6-(1h-imidazol-1-il)-2-fenilquinazolina.
WO2011104723A3 (en) Acid addition salts of ivabradine and preparation method thereof
IL215965A0 (en) Solvate crystals and methods of producing the same
IN2012DN02698A (enExample)
IT1400919B1 (it) "strumento per la lavorazione del terreno"
EP2349988A4 (en) ORGANIC NUTRIENT SALTS, PREPARATION METHODS AND USES THEREOF
HUP0900130A3 (en) Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 JAN 2017 BY DENNEMEYER SA

Effective date: 20131218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 JAN 2023 BY DENNEMEYER + CO

Effective date: 20140829

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 JAN 2020 BY DENNEMEYER + CO

Effective date: 20140828

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 14 JAN 2030 BY DENNEMEYER + CO

Effective date: 20140829